STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: The U.S. Food and Drug Administration (FDA) has approved Meda’s (STO:MEDAA) registration application for azelastine eye drops in unit dose (Optivar Unit Dose). The substance azelastine is an antihistamine and the eye drop formulation is approved for treatment of allergic conjunctivitis in adults and pediatrics.
